UNMC's technology transfer and commercialization office, UNeMed, negotiated the licensing agreement that pairs GenomOncology's powerful engine with the Campbells' elegant system. The system is called the Nebraska Lexicon Synoptic Pathology Reporting Module, and functions as an add-on to the most widely-used EHR terminology in the world, SNOMED CT.

"This doesn't happen without Scott Campbell and Jim Campbell," said Catherine Murari-Kanti, a licensing specialist at UNeMed. "But they can't do this without GenomOncology's platform. It's the perfect marriage."


GenomOncology's platform, now armed with the UNMC module, will do more than just help with diagnoses treatment plans. The system could make a dramatic impact in research, helping filter and enroll patients for clinical trials.

"There's a lot of cool stuff going on in oncology, and I think we're underserving the patient because we can't identify potential patients for trials and vice versa," Choi said.

By making the EHR a more useful database, researchers and clinicians can find potential patients or trial programs. They will no longer need to spend countless hours poring through attachment files.

"Less than 5 percent of cancer patients get enrolled in clinical trials," Choi said. "That number hasn't changed since the 1980s in part due to various informatics challenges. We can do a lot better than that."

UNeMed Corporation is the technology transfer and commercialization office for the University of Nebraska Medical Center. UNeMed serves all UNMC researchers, faculty and staff who develop new biomedical technology and inventions, and strives to help bring those innovations to the marketplace.

GenomOncology enables the application of genomics in oncology to improve patient care. We have applied our expertise in genomics, technology and data integration to create solutions for cancer care providers. Our solutions are end-to-end: from the data coming out of the sequencer to the bedside where oncologists make treatment decisions. Our technology streamlines workflow and creates actionable reports for pathologists. Downstream, we integrate molecular and clinical information, providing oncologists with powerful decision-support tools that enable treatment selection, patient identification for clinical trials, and a "patients-like-mine" feature for use in difficult cases – all delivered through a real-time platform. Our solutions also enable "Big Data" analysis of aggregate data to drive research and new insights.


SOURCE GenomOncology; University of Nebraska Medical Center

Back to HCB News

Health IT Homepage